Poland· PL-100384931

Anagrelid Nordic

A anagrelide product containing anagrelidum, registered in Poland by Nordic Group B.V.. The same ATC class is registered in 19 of our 19 countries.

ATC L01XX35

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedAnagrelid NordicATCL01XX35REGISTER NO.PL-100384931PACKS LISTED2CHECKEDSeptember 27, 2026

Where it is registered

Anagrelide is registered in 19 of 19 countries.

Countries holding a registration under ATC L01XX35 (anagrelide), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 11 of them publish a price we can compare per daily dose

Anagrelide · ATC L01XX35

19 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Italyprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Spainprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of anagrelide costs, country by country.

Normalised to the WHO defined daily dose (2 mg), so markets compare like for like.

  • 3 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Anagrelide · price per daily dose (2 mg)

USD · FX 28 Sept 2026

  • IT Italy$15.54
  • ES Spain$14.25
  • CH Switzerland$11.36
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

URPL (Poland)
Active substance
Anagrelidum
Manufacturer
Nordic Group B.V.
Country
Poland (PL)
ATC code
L01XX35
ATC class
Anagrelide
Defined daily dose
2 mg, O
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 2

  • gtin
    05909991398927
  • gtin
    05909991398934

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

438 interactions on record for anagrelide.

Graded by severity as the source publishes them — 274 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Anagrelide · interactions on record

438 records

  • 274 severe
  • 156 moderate
  • 4 minor
  • 4 info

Most severe, free to view

  • PapaverineA03AD01severe
  • CisaprideA03FA02severe
  • OndansetronA04AA01severe
  • GranisetronA04AA02severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Anagrelide in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All anagrelide products

Authorised across Europe · EMA

The same active substance is authorised in 29 EEA countries. Names it is sold under:

  • Austria · Anagrelid +pharma, Anagrelid Aop
  • Belgium · Anagrelid Sandoz, Atremia
  • Bulgaria · Тромборедуктин
  • Cyprus · Anagrelide Aop
  • Czechia · Anagrelid Stada, Anagrelide Teva
  • Germany · Anagrelid Abz, Anagrelid Al
  • Denmark · Anagrelid Bluefish, Anagrelide "stada"
  • Spain · Anagrelida Aurovitas, Anagrelida Bluefish
  • Finland · Anagrelid Avansor, Anagrelid Orion
  • France · Anagrelide Arrow, Anagrelide Biogaran
  • United Kingdom (Northern Ireland) · Anagrelide Bluefish, Anagrelide Brown & Burk Uk
  • Greece · Anagrelide Aop, Anagrelide Teva
  • Croatia · Anagrelid, Anagrelid Stada
  • Hungary · Adride, Anagrelide Stada
  • Ireland · Anagrelide Athlone Pharmaceuticals
  • Iceland · Anagrelide Bluefish, Anagrelide Viatris
  • Italy · Anagrelide Aurobindo, Anagrelide Sandoz
  • Liechtenstein · Anagrelide Viatris, Xagrid
  • Lithuania · Anagrelide Teva, Thromboreductin
  • Luxembourg · Atremia
  • Latvia · Thromboreductin
  • Malta · Anagrelide Torrent
  • Netherlands · Anagrelide Accord, Anagrelide Cf
  • Norway · Anagrelide Bluefish, Anagrelide Viatris
  • Portugal · Anagrelida Aurovitas, Anagrelida Bluefish
  • Romania · Anagrelidă Accord, Grenalvon
  • Sweden · Anagrelid Accordpharma, Anagrelid Avansor
  • Slovenia · Anagrelid Sandoz, Anagrelid Teva
  • Slovakia · Anagrelide Glenmark, Anagrelide Vipharm

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/e1963821-9cf9-4c2e-a880-31b111ccd0aa
GET /v1/drugs/e1963821-9cf9-4c2e-a880-31b111ccd0aa?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletki",
  "source": "urpl",
  "strength": "0,75 mg",
  "packaging": "05909991398927 ¦ Rpz ¦ 132099\n100 tabl. w butelce\n05909991398934 ¦ Rpz ¦ 132100\n100 tabl. w blistrze",
  "substance": "Anagrelidum 0,75 mg",
  "common_name": "Anagrelidum",
  "pl_product_id": "100384931",
  "pozwolenie_nr": "25243",
  "auth_procedure": "DCP",
  "authorisation_validity": "2024-04-03"
}

See everything about anagrelide.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.